KalVista Pharmaceuticals, Inc.

Listed Company

KALVCIK 0001348911NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-183.44M

Total Assets

$250.77M

Equity

$95.39M

Shares Out

53.24M

Op. Cash Flow

$-152.91M

KALV$26.99+89.94% · past yearDBEQ Basic

Daily closing prices

Business

KalVista Pharmaceuticals is a global biopharmaceutical company developing oral therapies for rare diseases with unmet medical needs. The company's lead product, EKTERLY (sebetralstat), a small-molecule oral plasma kallikrein inhibitor for acute hereditary angioedema attacks, received FDA approval in July 2025 and is the first oral on-demand HAE treatment. KalVista operates through direct commercial infrastructure in the U.S. and partnerships in select international markets including Japan and Canada.

Summary from 10-K filed 2025-07-10

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-04-30	FY 2024 2024-04-30	FY 2023 2023-04-30	FY 2022 2022-04-30	FY 2021 2021-04-30
Research and development	72	86	80	70	41
General and administrative	116	54	31	26	17
Total operating expenses	188	140	111	97	58
Operating loss	−188	−140	−111	−97	−58
Interest income	6	4	2	1	903,000
Interest (expense)	−6	—	—	—	—
Foreign currency exchange gain (loss)	2	138,000	90,000	−2	−847,000
Other income (expenses), net	5	10	16	15	10
Total other income	8	14	18	14	12
Loss before income taxes	−180	−127	−93	−82	−82
Income tax (benefit) expense	3	0	0	0	0
Net loss	−183	−127	−93	−82	−46
Foreign currency translation loss	−3	−394,000	−604,000	−1	1
Unrealized holding gain on marketable securities	2	1	1	−2	−473,000
Reclassification adjustment for realized (gain) loss on available for sale securities included in net loss	−2	−1	139,000	581,000	−153,000
Total other comprehensive (loss):	−2	−428,000	801,000	−2	450,000
Comprehensive loss	−185	−127	−92	−85	−46
Net loss per share, basic	−3.69	−3.44	−3.33	−3.36	−2.42
Net loss per share, diluted	−3.69	−3.44	−3.33	−3.36	−2.42
Weighted average common shares outstanding, basic	50	37	28	24	19
Weighted average common shares outstanding, diluted	50	37	28	24	19

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-04-30	FY 2024 2024-04-30	FY 2023 2023-04-30	FY 2022 2022-04-30	FY 2021 2021-04-30
Cash and cash equivalents	132	32	56	31	51
Marketable securities	89	179	93	135	198
Research and development tax credit receivable	1	8	17	14	10
Prepaid expenses and other current assets	20	7	6	13	5
Total current assets	242	226	172	194	264
Property and equipment, net	2	2	3	2	2
Right of use assets	6	7	8	8	6
Other assets	2	567,000	106,000	193,000	200,000
Total assets	251	235	183	204	272
Accounts payable	5	9	5	4	2
Accrued expenses	27	12	9	7	7
Lease liability - current portion	2	1	1	977,000	863,000
Deferred revenue	11	—	—	—	—
Total current liabilities	45	23	15	12	10
Lease liability - net of current portion	4	6	7	7	5
Deferred royalty obligation	106	—	—	—	—
Total long-term liabilities	110	6	7	7	5
Commitments and contingencies (Note 9)	—	—	—	—	—
Common stock, $0.001 par value, 100,000,000 authorized Shares issued and outstanding: 49,762,048 and 42,521,975 as of April 30, 2025 and 2024, respectively	50,000	42,000	34,000	25,000	24,000
Additional paid-in capital	754	680	507	439	426
Accumulated deficit	−653	−470	−343	−250	−168
Accumulated other comprehensive loss	−5	−3	−3	−4	−1
Total stockholders equity	95	207	161	185	257
Total liabilities and stockholders equity	251	235	183	204	272

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-04-30	FY 2024 2024-04-30	FY 2023 2023-04-30	FY 2022 2022-04-30	FY 2021 2021-04-30
Net loss	−183	−127	−93	−82	−46
Depreciation and amortization	900,000	800,000	700,000	564,000	537,000
Stock-based compensation expense	12	22	10	11	7
Realized (gain) loss from sale of marketable securities	−2	−1	139,000	581,000	—
Non-cash operating lease expense	370,000	−12,000	84,000	179,000	114,000
Amortization of premium on available for sale securities	14,000	92,000	988,000	3	685,000
Foreign currency exchange loss (gain)	−4	760,000	−2	2	−574,000
Fair value adjustment to derivative liability	2	—	—	—	—
Non-cash interest expense and amortization of issuance costs	6	—	—	—	—
Research and development tax credit receivable	7	8	−2	−5	7
Prepaid expenses and other assets	−1	−538,000	7	−9	−244,000
Other receivables	−11	—	—	—	—
Accounts payable	−5	4	1	2	150,000
Accrued expenses	14	3	2	472,000	983,000
Deferred revenue	11	—	—	—	—
Net cash used in operating activities	−153	−89	−75	−78	−30
Purchases of available for sale securities	−31	−189	−98	−137	−201
Sales and maturities of available for sale securities	123	105	141	196	54
Acquisition of property and equipment	−434,000	−42,000	−1	−931,000	−82,000
Capitalized website development costs	−495,000	−401,000	—	—	—
Net cash provided by investing activities	91	−85	41	58	−148
Proceeds from the royalty agreement	100	—	—	—	—
Issuance costs associated with the royalty agreement	−2	—	—	—	—
Issuance of common stock, net of offering expenses	56	97	57	—	211
Issuance of pre-funded warrants	—	53	1	—	—
Issuance of common stock from equity incentive plans	6	646,000	449,000	2	2
Net cash provided by financing activities	160	151	58	2	212
Effect of exchange rate changes on cash and cash equivalents	3	−1	1	−1	511,000
Net increase (decrease) in cash and cash equivalents	100	−24	26	−20	35
Right of use assets obtained in exchange for operating lease liabilities	725,000	162,000	1	3	5
Website development costs included in accounts payable	—	31,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is KalVista Pharmaceuticals, Inc.'s CIK number?

KalVista Pharmaceuticals, Inc.'s SEC CIK number is 0001348911 (1348911). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find KalVista Pharmaceuticals, Inc.'s SEC filings?

All of KalVista Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did KalVista Pharmaceuticals, Inc. last report earnings?

KalVista Pharmaceuticals, Inc. (KALV) most recently filed an earnings 8-K with the SEC on Mar 25, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-122784). This is KalVista Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is KalVista Pharmaceuticals, Inc.'s most recent earnings 8-K?

KalVista Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 25, 2026 under accession 0001193125-26-122784. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View KalVista Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →